Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection
ConditionLobectomy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTongji Hospital
About this trial
Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Eligibility criteria
Qualifiers
Age range: 18 to 75 years old;
Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
ASA classification levels I-III;
BMI 18 ~ 30 kg/m2。
Disqualifiers
Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
Pregnant or lactating women;
Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
Trial design
Treatments tested in this trial
- Tegileridine
- Intercostal Nerve Block
- Sufentanil
Treatment groups
118 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov